相关临床试验
5
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
1
20.0%
已完成
2
40.0%
尚未招募
1
20.0%
招募中
1
20.0%
暂无批准数据
- Swiss researchers engineered regulatory T cells with chimeric allergen receptors (CAlleRs) that specifically recognize birch pollen, reducing or preventing asthma symptoms in allergic mice. - The CAlleR Treg approach adapts CAR T cell technology from oncology to suppress, rather than activate, immune responses against common allergens. - In preclinical models, CAlleR Tregs decreased allergic inflammation, reduced mucus production, and improved lung function upon allergen re-exposure. - The study, published in JEM, provides proof-of-concept that this strategy could eventually treat severe allergic asthma and other allergies, including food allergens and house dust mites.
- Torqur AG's topical bimiralisib gel 2% demonstrated a 92% complete or near-complete response rate in patients with Olsen grade 1 actinic keratosis lesions in a phase 2 proof-of-concept study. - The randomized multicenter trial enrolled 46 patients across two Swiss dermatology centers, with 52% of patients in the 2-week cohort and 71% in the 4-week cohort achieving complete or partial lesion clearance. - The selective pan-PI3K/mTOR inhibitor showed favorable safety profile with only mild, localized skin reactions and four grade 2 events that resolved without intervention. - Torqur AG is now preparing for pivotal phase 3 clinical trials while discussing partnerships to advance this potential new treatment for the most common precancerous skin condition.
- New research from Swiss institutions demonstrates that age-related immune decline significantly reduces the effectiveness of CAR-T cell cancer therapy by impairing mitochondrial function and metabolism. - Scientists identified decreased levels of nicotinamide adenine dinucleotide (NAD) as the key factor behind reduced antitumor activity in CAR-T cells from older individuals. - Researchers successfully rejuvenated aged CAR-T cells by restoring NAD levels in preclinical models, suggesting potential strategies to improve immunotherapy outcomes in older cancer patients.
